companiesCompany
Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)
aka Rafael Pharmaceuticals
The company behind devimistat, a drug against cancer cell metabolism that failed its phase 3 trials in pancreatic cancer and leukaemia.
Overview
Rafael Pharmaceuticals, majority owned by Rafael Holdings, developed devimistat (CPI-613) for pancreatic cancer and acute myeloid leukaemia. After both phase 3 trials missed their endpoints in 2021 and 2022 the company was renamed Cornerstone Pharmaceuticals and refocused its pipeline.
Headquarters
Cranbury, New Jersey, United States, US
Scorecard
All companies#999of 1003 companies, score -1
- modalities +2
- failures -3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Type
biotech
Stage
Growth stage
Website
Similar pages
not linked directly; found by shared links- TrialAVENGER 500